| Literature DB >> 22212950 |
Tadashi Inuzuka1, Hiroki Nishikawa, Akira Sekikawa, Haruhiko Takeda, Shinichiro Henmi, Azusa Sakamoto, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio Osaki, Masatoshi Kudo.
Abstract
Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) were reported. Thereafter, only a relatively small number of CR cases were reported worldwide for sorafenib therapy. We herein report a case of CR in a patient treated with sorafenib for 4 months. The patient had advanced HCC with multiple lung metastases, and there has been no recurrence after 8 months following cessation of administration. To our knowledge, this is the first time a female treated with sorafenib alone for HCC has had a CR.Entities:
Mesh：
Substances：
Year: 2011 PMID： 22212950 DOI： 10.1159/000333279
Source DB: PubMed Journal: Oncology ISSN： 0030-2414 Impact factor: 2.935